Collegium Pharmaceutical Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $809.76 million
- Book Value:
- Revenue TTM:
- $463.93 million
- Operating Margin TTM:
- Gross Profit TTM:
- $345.74 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Collegium Pharmaceutical Inc had its IPO on 2015-05-07 under the ticker symbol COLL.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Collegium Pharmaceutical Inc has a staff strength of 207 employees.
Shares of Collegium Pharmaceutical Inc opened at $22.82 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $22.67 - $23.99, and closed at $23.77.
This is a +3.35% increase from the previous day's closing price.
A total volume of 370,512 shares were traded at the close of the day’s session.
In the last one week, shares of Collegium Pharmaceutical Inc have slipped by -2.18%.
Collegium Pharmaceutical Inc's Key Ratios
Collegium Pharmaceutical Inc has a market cap of $809.76 million, indicating a price to book ratio of 3.8595 and a price to sales ratio of 2.0913.
In the last 12-months Collegium Pharmaceutical Inc’s revenue was $463.93 million with a gross profit of $345.74 million and an EBITDA of $172.26 million. The EBITDA ratio measures Collegium Pharmaceutical Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Collegium Pharmaceutical Inc’s operating margin was 7.18% while its return on assets stood at 2.23% with a return of equity of -12.57%.
In Q4, Collegium Pharmaceutical Inc’s quarterly earnings growth was a negative -95.5% while revenue growth was a positive 373.7%.
Collegium Pharmaceutical Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 4.4444 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Collegium Pharmaceutical Inc’s profitability.
Collegium Pharmaceutical Inc stock is trading at a EV to sales ratio of 3.7576 and a EV to EBITDA ratio of 13.5205. Its price to sales ratio in the trailing 12-months stood at 2.0913.
Collegium Pharmaceutical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.17 billion
- Total Liabilities
- $39.62 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Collegium Pharmaceutical Inc ended 2023 with $1.17 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.17 billion while shareholder equity stood at $194.84 million.
Collegium Pharmaceutical Inc ended 2023 with $0 in deferred long-term liabilities, $39.62 million in other current liabilities, 37000.00 in common stock, $-281344000.00 in retained earnings and $133.70 million in goodwill. Its cash balance stood at $173.69 million and cash and short-term investments were $173.69 million. The company’s total short-term debt was $163,612,000 while long-term debt stood at $538.45 million.
Collegium Pharmaceutical Inc’s total current assets stands at $403.31 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $183.12 million compared to accounts payable of $39.62 million and inventory worth $46.50 million.
In 2023, Collegium Pharmaceutical Inc's operating cash flow was $-940000.00 while its capital expenditure stood at $940000.
Comparatively, Collegium Pharmaceutical Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Collegium Pharmaceutical Inc stock is currently trading at $23.77 per share. It touched a 52-week high of $30.22 and a 52-week low of $30.22. Analysts tracking the stock have a 12-month average target price of $36.4.
Its 50-day moving average was $26.65 and 200-day moving average was $20.95 The short ratio stood at 8.08 indicating a short percent outstanding of 0%.
Around 169.6% of the company’s stock are held by insiders while 11023.2% are held by institutions.
Frequently Asked Questions About Collegium Pharmaceutical Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.